KR20190008896A - 변이체 플라비바이러스 엔벨로프 서열 및 그의 용도 - Google Patents

변이체 플라비바이러스 엔벨로프 서열 및 그의 용도 Download PDF

Info

Publication number
KR20190008896A
KR20190008896A KR1020187036317A KR20187036317A KR20190008896A KR 20190008896 A KR20190008896 A KR 20190008896A KR 1020187036317 A KR1020187036317 A KR 1020187036317A KR 20187036317 A KR20187036317 A KR 20187036317A KR 20190008896 A KR20190008896 A KR 20190008896A
Authority
KR
South Korea
Prior art keywords
dengue
protein
flavivirus
analog
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020187036317A
Other languages
English (en)
Korean (ko)
Inventor
피터 라잉
Original Assignee
엑시비온 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엑시비온 리미티드 filed Critical 엑시비온 리미티드
Publication of KR20190008896A publication Critical patent/KR20190008896A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
    • C07K14/1825—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/185—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
KR1020187036317A 2016-05-20 2017-05-22 변이체 플라비바이러스 엔벨로프 서열 및 그의 용도 Abandoned KR20190008896A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1608896.5 2016-05-20
GB1608896.5A GB2550418A (en) 2016-05-20 2016-05-20 An improved vaccine against flaviviruses avoiding elicitation or stimulation of infection-enhancing antibodies
PCT/US2017/033882 WO2017201543A1 (en) 2016-05-20 2017-05-22 Variant flavivirus envelope sequences and uses thereof

Publications (1)

Publication Number Publication Date
KR20190008896A true KR20190008896A (ko) 2019-01-25

Family

ID=56369688

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187036317A Abandoned KR20190008896A (ko) 2016-05-20 2017-05-22 변이체 플라비바이러스 엔벨로프 서열 및 그의 용도

Country Status (18)

Country Link
US (2) US11028133B2 (https=)
EP (2) EP3458471B1 (https=)
JP (1) JP7121396B2 (https=)
KR (1) KR20190008896A (https=)
CN (1) CN109415414A (https=)
AU (1) AU2017268479B2 (https=)
BR (1) BR112018073681A2 (https=)
CA (1) CA3025076A1 (https=)
DK (1) DK3458471T3 (https=)
GB (2) GB2550418A (https=)
HU (1) HUE049543T2 (https=)
IL (1) IL263054A (https=)
MX (1) MX2018014198A (https=)
PE (1) PE20190130A1 (https=)
PH (1) PH12018502441A1 (https=)
RU (1) RU2018142835A (https=)
SG (1) SG11201810157QA (https=)
WO (2) WO2017201543A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2550418A (en) * 2016-05-20 2017-11-22 Laing Peter An improved vaccine against flaviviruses avoiding elicitation or stimulation of infection-enhancing antibodies
EP3474891B1 (en) * 2016-06-23 2021-01-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Vaccine compositions comprising an attenuated mutant zika virus
EP3621645A4 (en) 2017-05-10 2021-01-27 University of Massachusetts BIVALENT VACCINES AGAINST DENGUE / HEPATITIS B
TWI658848B (zh) * 2018-02-13 2019-05-11 National Tsing Hua University 茲卡病毒疫苗組合物及其應用
CN109627294B (zh) * 2018-12-29 2020-10-09 四川大学 一种正确折叠的重组狂犬病毒g蛋白胞外段及其潜在应用
WO2020198865A1 (en) * 2019-04-03 2020-10-08 The University Of British Columbia Oligopeptides for quantitative viral proteomic analysis methods and uses
KR20220093197A (ko) * 2019-11-07 2022-07-05 인스티튜트 오브 마이크로바이올로지, 차이니즈 아카데미 오브 사이언스즈 지카/뎅기열 백신 및 이의 응용
WO2022074111A1 (en) * 2020-10-07 2022-04-14 Sanofi Pasteur Improved diagnostic tests
CN117157524A (zh) * 2020-10-07 2023-12-01 赛诺菲巴斯德有限公司 改良的诊断测试
GB202019843D0 (en) 2020-12-16 2021-01-27 Coronex Ltd Lateral flow tests
EP4602057A1 (en) * 2022-10-11 2025-08-20 University of Maryland, Baltimore Engineered flavivirus envelope glycoprotein immunogenic compositions and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1057534C (zh) 1993-08-17 2000-10-18 柯瑞英-艾格公司 促红细胞生成素类似物
CA2616026A1 (en) * 2005-07-22 2007-02-08 Research Development Foundation Attenuated strains of flaviviruses , and uses thereof
US7943148B1 (en) * 2007-04-04 2011-05-17 The United States Of America As Represented By The Secretary Of The Army Amino acid sites in Flavivirus E proteins useful for development of diagnostics and vaccines
US9821050B2 (en) * 2012-04-02 2017-11-21 The University Of North Carolina At Chapel Hill Chimeric dengue virus E glycoproteins comprising mutant domain I and domain II hinge regions
GB201413086D0 (en) * 2014-07-23 2014-09-03 Imp Innovations Ltd And Inst Pasteur Methods
GB2550418A (en) * 2016-05-20 2017-11-22 Laing Peter An improved vaccine against flaviviruses avoiding elicitation or stimulation of infection-enhancing antibodies

Also Published As

Publication number Publication date
JP2019520058A (ja) 2019-07-18
US20200215180A1 (en) 2020-07-09
US11028133B2 (en) 2021-06-08
WO2018215495A1 (en) 2018-11-29
JP7121396B2 (ja) 2022-08-18
DK3458471T3 (da) 2020-07-06
AU2017268479B2 (en) 2021-04-01
WO2017201543A1 (en) 2017-11-23
US11401307B2 (en) 2022-08-02
EP3458471A1 (en) 2019-03-27
GB201719423D0 (en) 2018-01-03
EP3458471B1 (en) 2020-03-25
RU2018142835A (ru) 2020-06-22
PE20190130A1 (es) 2019-01-17
BR112018073681A2 (pt) 2019-02-26
SG11201810157QA (en) 2018-12-28
HUE049543T2 (hu) 2020-09-28
CN109415414A (zh) 2019-03-01
PH12018502441A1 (en) 2019-05-15
EP3630796A1 (en) 2020-04-08
IL263054A (en) 2019-01-31
US20190300580A1 (en) 2019-10-03
MX2018014198A (es) 2019-08-21
CA3025076A1 (en) 2017-11-23
GB201608896D0 (en) 2016-07-06
GB2550418A (en) 2017-11-22
AU2017268479A1 (en) 2018-12-06

Similar Documents

Publication Publication Date Title
KR20190008896A (ko) 변이체 플라비바이러스 엔벨로프 서열 및 그의 용도
Sánchez et al. Characterization of neutralizing antibodies to West Nile virus
US11926648B2 (en) Neutralising antibody against dengue for use in a method of prevention and/or treatment of Zika infection
Costa et al. DNA vaccines against dengue virus based on the ns1 gene: the influence of different signal sequences on the protein expression and its correlation to the immune response elicited in mice
Lieberman et al. Preparation and immunogenic properties of a recombinant West Nile subunit vaccine
RU2274643C2 (ru) Выделенный оболочечный белок hcv, способ его получения и лекарство, вакцина, фармацевтическая композиция (варианты) его содержащие
Block et al. A tetravalent recombinant dengue domain III protein vaccine stimulates neutralizing and enhancing antibodies in mice
AU2022257113B2 (en) Improved coronavirus vaccine
Chen et al. A consensus envelope protein domain III can induce neutralizing antibody responses against serotype 2 of dengue virus in non-human primates
Staropoli et al. Affinity-purified dengue-2 virus envelope glycoprotein induces neutralizing antibodies and protective immunity in mice
KR20130138789A (ko) 재조합 서브유닛 뎅기 바이러스 백신
JP2001511459A (ja) フラビウイルス感染に対抗する組換え二量体エンベロープワクチン
US12064476B2 (en) Zika virus immunogenic compositions
CN102481355A (zh) 用于保护人受试者的重组亚单位西尼罗病毒疫苗
Shin et al. Plant-expressed Zika virus envelope protein elicited protective immunity against the Zika virus in immunocompetent mice
AU2020325279A1 (en) Methods and compositions for stabilized recombinant flavivirus E protein dimers
Wang et al. Rational design of flavivirus E protein vaccine optimizes immunogenicity and mitigates antibody dependent enhancement risk
KR101966841B1 (ko) 지카바이러스 e 단백질 유래의 재조합 항원 및 이의 용도
US20220017605A1 (en) Human antibodies targeting zika virus ns1, ns1 polypeptides and uses thereof
JP6983653B2 (ja) ワクチン
US7595053B2 (en) Chimeric T helper-B cell peptide vaccine for Japanese encephalitis virus
US20050287170A1 (en) Subunit vaccine against West Nile viral infection
HK1261267A1 (en) Variant flavivirus envelope sequences and uses thereof
Calvert et al. The use of human monoclonal antibodies to study the structure and function of the West Nile virus prM protein
KR20210027285A (ko) 플라비바이러스의 성숙 바이러스-유사 입자

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PC1904 Unpaid initial registration fee

St.27 status event code: A-2-2-U10-U14-oth-PC1904

St.27 status event code: N-2-6-B10-B12-nap-PC1904